Results 301 to 310 of about 514,942 (384)

Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia. [PDF]

Arch Pharm (Weinheim)
Irgit A, Kamıs R, Sever B, Tuyun AF, Otsuka M, Fujita M, Demirci H, Ciftci H.   +7 more
europepmc   +1 more source

Genomics Review of Selective RET Inhibitors Sensitivity in Thyroid Cancer Clinical Trials

American Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT RET gene is a driver of thyroid cancer (TC) tumorigenesis. The incidence of TC has increased worldwide in the last few decades, both in medullary and follicular‐derived subtypes. Several drugs, including multikinase and selective inhibitors, have been explored.
Sara Gil‐Bernabé, Lucía García‐DeLaFuente, Alejandro García‐Álvarez, Ginesa García‐Rostán, Jaume Capdevila, Jorge Hernando   +5 more
wiley   +1 more source

The ATM Kinase Inhibitor AZD0156 Is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4‐Kinase (PI4Kβ) and Is an Attractive Candidate for Medicinal Chemistry Optimization Against Malaria

Angewandte Chemie, EarlyView.
AZD0156, an ATM kinase inhibitor in clinical development, shows promising multistage antiplasmodial activity by targeting Plasmodium falciparum phosphatidylinositol 4‐kinase (PfPI4Kβ). With an improved specificity profile relative to other PfPI4Kβ inhibitors and moderate efficacy in a P.
John G. Woodland, Dina Coertzen, Kathryn J. Wicht, Virginia Franco Hidalgo, Charisse Flerida A. Pasaje, Luiz C. Godoy, Tarrick Qahash, Mmakwena M. Mmonwa, Godwin A. Dziwornu, Lynn Wambua, Sarah Harries, Constance M. Korkor, Mathew Njoroge, Liezl Krugmann, Dale Taylor, Meta Leshabane, Henrico Langeveld, Tayla Rabie, Janette Reader, Mariëtte van der Watt, Nelius Venter, Erica Erlank, Ayesha S. Aswat, Lizette L. Koekemoer, Tomas Yeo, Jin H. Jeon, David A. Fidock, Francisco Javier Gamo, Sergio Wittlin, Jacquin C. Niles, Manuel Llinas, Lauren B. Coulson, Lyn‐Marié Birkholtz, Kelly Chibale   +33 more
wiley   +2 more sources

New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond

Annals of Neurology, EarlyView.
The advances achieved against multiple sclerosis (MS) represent one of the great success stories of modern molecular medicine. The development of therapies with increasing selectivity and safety, guided by gains in understanding the fundamental immunology, neurobiology, genetics, and triggers of this disease, have broadened the traditional focus on ...
Joseph J. Sabatino Jr., Bruce A. C. Cree, Stephen L. Hauser   +2 more
wiley   +1 more source

Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology

Angewandte Chemie, EarlyView.
Targeted protein degradation (TPD) has emerged as a powerful therapeutic approach, with numerous candidates molecules now advancing into clinical development. Recent innovations have incorporated nanoparticles to facilitate and enhance these degradation processes, yielding synergistic effects.
Andrew G. Baker, Adrian Pui Ting Ho, Laura S. Itzhaki, Ljiljana Fruk   +3 more
wiley   +2 more sources

Autosomal Recessive Cerebellar Ataxias: Translating Genes to Therapies

Annals of Neurology, EarlyView.
Autosomal recessive cerebellar ataxias are disabling neurodegenerative genetic conditions affecting balance and coordination. Advancements in genomic testing have improved diagnosis, leading to a new focus on the development of targeted precision therapeutics addressing cellular, biochemical, and genetic disease mechanisms with a resulting emphasis on ...
Brent L. Fogel, Thomas Klopstock, David R. Lynch, Francesca Maltecca, Mayank Verma, Berge A. Minassian, Frances M. Platt, Débora Farina Gonçalves, Hélène Puccio, Andreas Roos, Matthis Synofzik   +10 more
wiley   +1 more source

Multiple and Alternative Sites Make Tau Protein an Adaptable Sticky Surface for the SH3 Domain of Fyn Kinase

Angewandte Chemie, EarlyView.
An NMR‐based study, combined with computational, calorimetric and in‐cell FRET methods, sheds light on the complex recognition mechanism between the intrinsically disordered protein Tau and the SH3 domain of Fyn kinase, highlighting how the multiple binding sites present in Tau make the protein an adaptable recognition surface that can function even ...
Roberto Tira, Giulia Leo, Laura Prandini, Carlo Giorgio Barracchia, Mariapina D'Onofrio, Luca Mollica, Stefano Capaldi, Michael Assfalg, Francesca Munari   +8 more
wiley   +2 more sources

Site-Specific Competitive Kinase Inhibitor Target Profiling Using Phosphonate Affinity Tags. [PDF]

Mol Cell Proteomics
van Bergen W, Nederstigt AE, Heck AJR, Baggelaar MP.   +3 more
europepmc   +1 more source

PROTAC Technology as a New Tool for Modern Pharmacotherapy. [PDF]

Molecules
Kubryń N, Fijałkowski Ł, Nowaczyk J, Jamil A, Nowaczyk A.   +4 more
europepmc   +1 more source

Regulation of Synaptic NMDA Receptor Activity by Post-Translational Modifications. [PDF]

Neurochem Res
Tahiri E, Corti E, Duarte CB.
europepmc   +1 more source